Tocilizumab for chronic active antibody-mediated rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your kidney function (eGFR) must be above 25 mL/min.
- A kidney biopsy must show certain changes (chronicity score less than 8 and IFTA less than 40%).
- You must have had the Epstein-Barr virus (EBV) in the past (test positive for antibodies).
- You cannot have an active infection or a recent cancer (unless in remission for over 2 years).
- Your platelet count and liver function tests must be normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
This study looks at different treatments for a type of kidney transplant rejection called antibody-mediated rejection, where the body's immune system attacks the new kidney. It aims to understand how these treatments work and how they might help people keep their transplanted kidney healthy.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.